Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 178.12B |
| Revenue (ttm) | 47.05B |
| Net Income (ttm) | 11.37B |
| Shares Out | 1.96B |
| EPS (ttm) | 5.64 |
| PE Ratio | 16.13 |
| Forward PE | 12.79 |
| Dividend | 3.50 (3.85%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 5,885,455 |
| Average Volume | 3,986,994 |
| Open | 88.41 |
| Previous Close | 90.91 |
| Day's Range | 88.08 - 91.87 |
| 52-Week Range | 81.10 - 102.72 |
| Beta | 0.53 |
| RSI | 46.74 |
| Earnings Date | Apr 29, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Novartis to keep making malaria drugs if orders dry up amid aid cuts
Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters...
Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.
The president says big news about drug pricing is coming next week.
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
China sees global turmoil as opportunity to be ‘business friendly’, says Novartis chief
Vas Narasimhan argues potential US tariffs on pharma industry are not ‘sensible’
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
– Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025 , NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephien...
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...
BioNTech says Novartis executive Zapata-Gomez to become CFO
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal
Key deals this week: Gold Fields, Palo Alto, Novartis, LendingClub and more
Final Trade: NVS, XLU and SMMT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: NVS, XLU and SMMT
The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.
Regulus CVR may be worth $3-$4 a share in Novartis deal - analyst
Regulus Therapeutics (RGLS) sale to Novartis offers $7/share upfront & CVR worth $3-$4/share.
Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday. The Dow traded down 0.47% to 40,335.51 while the NASDAQ dipped 1.22% to 17,248.37. The S&P 500 ...
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis AG (NYSE: NVS) agreed to acquire Regulus Therapeutics Inc. (NASDAQ: RGLS) on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion . The upfront cash portion of the co...
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
Novartis: 2025 Guidance Raised To Top End Of Prior Range - Buy Confirmed
Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis
In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure...
Novartis to Acquire Regulus in $1.7 Billion Deal
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.